195 related articles for article (PubMed ID: 19747139)
1. Selective matrix metalloproteinase inhibitors for cancer.
Lia NG; Shib ZH; Tang YP; Duan JA
Curr Med Chem; 2009; 16(29):3805-27. PubMed ID: 19747139
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.
Sang QX; Jin Y; Newcomer RG; Monroe SC; Fang X; Hurst DR; Lee S; Cao Q; Schwartz MA
Curr Top Med Chem; 2006; 6(4):289-316. PubMed ID: 16611144
[TBL] [Abstract][Full Text] [Related]
4. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
5. [Expression of matrix metalloproteinases in patients with malignant tumors].
Stanciūte D; Didziapetriene J; Kadziauskas J
Medicina (Kaunas); 2004; 40(12):1143-50. PubMed ID: 15630339
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.
Nuti E; Tuccinardi T; Rossello A
Curr Pharm Des; 2007; 13(20):2087-100. PubMed ID: 17627541
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
Peterson JT
Heart Fail Rev; 2004 Jan; 9(1):63-79. PubMed ID: 14739769
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
Li NG; Tang YP; Duan JA; Shi ZH
Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
[TBL] [Abstract][Full Text] [Related]
9. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
Pirard B
Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors?
Corbitt CA; Lin J; Lindsey ML
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):135-42. PubMed ID: 18221058
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
12. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
13. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
[TBL] [Abstract][Full Text] [Related]
14. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
Overall CM; Kleifeld O
Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Rudek MA; Venitz J; Figg WD
Pharmacotherapy; 2002 Jun; 22(6):705-20. PubMed ID: 12066962
[TBL] [Abstract][Full Text] [Related]
16. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
Alcantara MB; Dass CR
J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
[TBL] [Abstract][Full Text] [Related]
17. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
18. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2004 Nov; 11(22):2911-77. PubMed ID: 15544483
[TBL] [Abstract][Full Text] [Related]
19. Towards third generation matrix metalloproteinase inhibitors for cancer therapy.
Overall CM; Kleifeld O
Br J Cancer; 2006 Apr; 94(7):941-6. PubMed ID: 16538215
[TBL] [Abstract][Full Text] [Related]
20. Structural studies of matrix metalloproteinases.
Borkakoti N
J Mol Med (Berl); 2000; 78(5):261-8. PubMed ID: 10954198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
